Peptide Dosages

cropped-pdlogo-nr

Peptide
Dosages

Menu

Prostamax (20mg Vial) Dosage Protocol

Contents

Quickstart Highlights

Prostamax is a synthetic bioregulator tetrapeptide (Lys‑Glu‑Asp‑Pro) described as prostate‑tissue–specific in preclinical literature[1]. Short peptides can interact with DNA/chromatin and influence gene expression programs[2], and several ultrashort peptides show cellular uptake via peptide/amino‑acid transporters[3][4]. This educational protocol presents a once‑daily subcutaneous approach, drawing from daily parenteral schedules in animal studies and general best practices for subcutaneous peptide delivery.

  • Reconstitute: Add 3.0 mL bacteriostatic water → concentration ≈ 6.67 mg/mL. At this dilution, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
  • Suggested daily titration range (educational): 500–3000 mcg once daily with gradual increases, reflecting daily parenteral use in preclinical work and typical SC tolerability limits[1][7].
  • Storage: Keep lyophilized vials cold (e.g., −20 °C [−4 °F]) and protected from light; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw cycles[11][12][13].
Prostamax (20mg Vial)
📘 Important: Before viewing any protocol, please consult our Prep & Injection Guide for essential preparation and safety instructions.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Route & Frequency: Inject once daily by the subcutaneous route. Animal data with Prostamax used daily parenteral dosing (intramuscular injections) for 15 days[1]. Subcutaneous administration is widely used for peptide therapeutics, and volumes up to ~3.0 mL in the abdomen are generally well tolerated in adults[7].

Standard / Gradual Approach (3.0 mL → ~6.67 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 500 mcg 7.5 units (0.08 mL)
Weeks 3–4 1000 mcg 15 units (0.15 mL)
Weeks 5–6 2000 mcg 30 units (0.30 mL)
Weeks 7–12 3000 mcg 45 units (0.45 mL)

Measuring notes: 20 mg ÷ 3.0 mL = 6.67 mg/mL → 6667 mcg/mL. On a U‑100 syringe, 1 unit = 0.01 mL ≈ 66.7 mcg. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Using aseptic technique, draw 3.0 mL bacteriostatic water for injection (multi‑dose diluent with benzyl alcohol)[11].
  2. Inject slowly down the vial wall; allow the powder to dissolve fully (gently swirl; do not shake).
  3. Label the vial and store at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycling[12][13].
Evidence context: Human dosing and clinical efficacy data for Prostamax are limited; the schedule above reflects cautious extrapolation from preclinical daily parenteral dosing and general SC administration principles for peptides[1][7].

Supplies Needed

Planning estimates for 8–16 weeks of once‑daily subcutaneous injections (units/day × days; vials rounded up; bacteriostatic water equals reconstitution volume × vials).

  • Peptide Vials (Prostamax, 20 mg each):
    • 8 weeks ≈ 5 vials
    • 12 weeks ≈ 9 vials
    • 16 weeks ≈ 13 vials
  • Insulin Syringes (U‑100):
    • Per week: 7 (1/day)
    • 8 weeks: 56
    • 12 weeks: 84
    • 16 weeks: 112
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial.
    • 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
    • 12 weeks (9 vials): 27 mL → 3 × 10 mL bottles
    • 16 weeks (13 vials): 39 mL → 4 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper and one for the injection site daily.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112
    • 12 weeks: 168
    • 16 weeks: 224
Peptide Vial
Insulin Syringes
Bacteriostatic Water
Alcohol Pads

Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Educational framework to explore prostate‑tissue support signals observed in preclinical models (reduced inflammatory and fibrotic markers)[1].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (optional extension to 16 weeks).
  • Dose Range: 500–3000 mcg daily with gradual titration.
  • Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for clear syringe conversions.
  • Storage: Lyophilized at −20 °C (−4 °F); reconstituted at 2–8 °C (35.6–46.4 °F); minimize freeze–thaw[12][13].

Dosing Protocol

Suggested daily titration approach with cautious evidence framing.

  • Start: 500–1000 mcg once daily; increase by ~500–1000 mcg every 1–2 weeks as tolerated.
  • Target: 2000–3000 mcg once daily by Weeks 5–8.
  • Rationale: Aligns with daily parenteral schedules in animal data and SC volume tolerability in adults[1][7].
  • Timing: Any consistent time of day; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Keep cold (e.g., −20 °C [−4 °F]) in dry/dark conditions; minimize moisture exposure[12][13].
  • Reconstituted: Refrigerate 2–8 °C (35.6–46.4 °F); consider aliquots; avoid repeated freeze–thaw[12][13].
  • Allow vial to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in an approved sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to minimize lipohypertrophy and variability in absorption[14][16].
  • Subcutaneous technique: insert at 45° into subcutaneous tissue; aspiration is not required[5][6].
  • Follow WHO/NCBI injection best‑practice guidance for asepsis and preparation[8].

How This Works

Prostamax (Lys‑Glu‑Asp‑Pro) is reported to be prostate‑tissue–specific in animal models[1]. Short peptides may directly interact with nucleosomal DNA and regulatory proteins, modulating transcriptional programs[2]. Multiple ultrashort peptides demonstrate transporter‑mediated cellular uptake (e.g., LAT, PEPT families)[3][4]. Select Khavinson‑family peptides have shown anti‑inflammatory cytokine modulation in immune models (e.g., reduced TNF‑α/IL‑6 signaling)[10].

Lifestyle Factors

Complementary strategies for best outcomes (general health guidance).

  • Balanced, protein‑forward nutrition matched to energy needs.
  • Combine resistance and aerobic activity to support metabolic health.
  • Prioritize sleep and stress management for adherence and recovery.

Potential Benefits & Side Effects

Highlights from preclinical and mechanistic literature (human clinical data remain limited).

  • Potential benefits (preclinical): Reduced histologic markers of chronic prostatic inflammation and sclerosis in a rat model with daily parenteral dosing[1].
  • Mechanistic signals: Short peptides can influence gene expression and may attenuate pro‑inflammatory cytokine signaling in immune systems[2][10].
  • Tolerability: For subcutaneous injections in adults, per‑dose volumes up to ~3.0 mL in the abdomen are generally well tolerated; larger volumes can increase pain/discomfort[7].
  • Local reactions: Mild injection‑site redness/itch/tenderness may occur; rotate sites to reduce risk of lipohypertrophy and tissue irritation[14][16].

Injection Technique

Subcutaneous administration pointers from reputable sources.

  • Clean stopper and skin with alcohol; allow to dry (aseptic technique per WHO/NCBI guidance)[8].
  • Pinch skinfold; insert the needle at 45° into subcutaneous tissue; inject slowly and steadily[5][6].
  • Do not aspirate for subcutaneous injections[5][6].
  • Rotate sites systematically (abdomen, thighs, upper arms) to minimize lipohypertrophy and absorption variability[14][16].

Recommended Source

We recommend Prime Lab Peptides for Prostamax (20 mg).

Why Prime Lab Peptides?

  • High‑purity batches with third‑party documentation.
  • Consistent handling and quality controls.
  • Reliable fulfillment with clear product specifications.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References


  • Modern Research in Inflammation (2013)
    — Rat model of chronic aseptic prostatitis: Prostamax (Lys‑Glu‑Asp‑Pro) daily IM (20 µg/kg) reduced inflammatory and fibrotic markers.
    View Source

  • Molecules (2021)
    — Systematic review: short peptides (≤7 aa) can enter nuclei and interact with DNA/chromatin to regulate gene expression.
    View Source

  • Int. J. Mol. Sci. (2022)
    — Review of ultrashort‑peptide transport via POT/LAT transporters across tissues.
    View Source

  • Biomedicines (2023)
    — Transport feasibility of 26 ultrashort peptides via LAT/PEPT carriers (modeling and docking).
    View Source

  • CDC — Vaccine Administration (2025)
    — Subcutaneous route technique (angle/site); aspiration not required.
    View Source

  • CDC (2024) — Subcutaneous Injection PDF
    — Visual guidance for subcutaneous injections; no aspiration.
    View Source

  • J. Pharm. Sci. (2019)
    — Subcutaneous injection: factors and tolerated volumes; up to ~3 mL in abdomen generally well tolerated.
    View Source

  • NCBI Bookshelf (WHO)
    — Best practices for injections: aseptic prep, administration steps, safe handling.
    View Source

  • DailyMed — Bacteriostatic Water for Injection (USP)
    — Official label: multi‑dose diluent with benzyl alcohol for drug reconstitution.
    View Source

  • Int. J. Mol. Sci. (2022)
    — Khavinson peptides modulate inflammatory cytokines (THP‑1 models; TNF‑α/IL‑6).
    View Source

  • DailyMed — Bacteriostatic Water (PDF label)
    — Composition and use as diluent; handling cautions.
    View Source

  • Pharmaceutics (2024)
    — Practical guidance for lyophilized protein drug products; stability of reconstituted solutions often studied at 2–8 °C.
    View Source

  • Pharmaceutics (2025)
    — Regulatory/stability overview for biologics: common storage at 2–8 °C; long‑term at sub‑zero as appropriate.
    View Source

  • Diabetes Spectrum (2019)
    — Injection technique: rotate SC sites to prevent lipohypertrophy and absorption variability.
    View Source

  • NCBI Bookshelf — Endotext (2023)
    — Insulin administration: site selection and rotation principles relevant to SC injections.
    View Source